AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Zenas BioPharma, Inc.

$28.39 -$6.11 (-17.71%)
NASDAQ · 30 Oct 2026 20:00 UTC
Previous Close
$28.76
Day Range
$27.91$28.75
Year Range
$13.50$44.60
Market Cap
1.85B
AVG Volume
767.37K
Trailing/Forward PE
-2.95/-
PEG ratio
-0.08
Dividend Yield
-
Next Earnings Date
2026-11-18
Primary Exchange
NASDAQUS
Revenue (USD) · A
020M40M60M202320242025
ZBIO Revenue (USD) by year
PeriodRevenue (USD)
202510M
20245M
202350M
Net Income (USD) · A
-400M-300M-200M-100M0202320242025
ZBIO Net Income (USD) by year
PeriodNet Income (USD)
2025-377.74M
2024-156.99M
2023-37.12M
Operating Income (USD) · A
-400M-300M-200M-100M0202320242025
ZBIO Operating Income (USD) by year
PeriodOperating Income (USD)
2025-383.06M
2024-163.89M
2023-37.15M
EBITDA · A
Cash Flows · A
EPS · A
Expenses · A
Cash & Debt · A
Debt ratios · A
Margins · A
Return on Capital · A
Shares Outstanding · A
Dividends (USD) · A
Employee Count
Book Value Per Share · A
Total Assets · A
PE Ratio
Free Cash Flow Yield
Price to Sales
EV/EBITDA
Price/Operating Cashflow
Price to Book

Earnings: ZBIO

Estimate against actual revenue and earnings per share, the beat and miss record of recent reports, and how the price moved around each one. Next report: 18 Nov 2026.

Zenas BioPharma, Inc.
ZBIO
Stockpicker

Video analysis: ZBIO

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ZBIO

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.